AOD-9604
AOD-9604
AOD-9604 is discussed for fat metabolism and weight support, but it is still waiting on clearer federal treatment after PCAC referral.
Current status
Under Review
Metabolic-related interest, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Reform interest remains high because clinics want a compliant metabolic peptide option.
Primary Use
Metabolic-related interest
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Sep 19, 2024
Current status signal recorded: Removed from the most restrictive bucket and sent for review..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when AOD-9604 status changes
State-specific notes
New York
Pharmacies still wait for formal follow-through.